What is the translation of " MULTICENTER " in Croatian?

• multicentričnom
• multicentrična
• multicentrično

Examples of using Multicenter in English and their translations into Croatian

A multicenter, randomized, placebo-controlled phase IIb study.
Multicentar, randomizirano, placebo kontrolirano ispitivanje faze IIb.

Most of the primary immunogenicity studies were conducted as randomized, controlled, multicenter, clinical trials.
Većina primarnih ispitivanja imunogenosti provedena su kao randomizirana, kontrolirana, multicentrična klinička ispitivanja.

START was a randomised, multicenter, double-blind, 3-arm, parallel-group safety study.
START je bilo randomizirano, multicentrično, dvostruko slijepo ispitivanje sigurnosti primjene u 3 paralelne skupine bolesnika.

The safety of subcutaneous tocilizumab in RA includes a double-blind, controlled, multicenter study, SC-I.
Ocjena sigurnosti tocilizumaba za supkutanu primjenu u bolesnika s RA uključuje dvostruko slijepo, kontrolirano, multicentrično ispitivanje SC-I.

The efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: SPIRIT and EXPRESS.
Djelotvornost infliksimaba ispitivana je u dva multicentrična, randomizirana, dvostruko slijepa, klinička ispitivanja: SPIRIT i EXPRESS.

A multicenter, randomized, open-label study was conducted in 1052 chemotherapy-naive patients with Stage IIIb/IV non-small cell lung cancer.
Multicentrično, randomizirano, otvoreno ispitivanje provedeno je u 1052 bolesnika s karcinomom nemalih stanica pluća IIIb/IV stadija, koji prije nisu bili liječeni kemoterapijom.

Study 02507 was a randomized, double-blind, placebo-controlled, multicenter clinical study in 40 patients with GD1.
Ispitivanje 02507 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano, multicentrično kliničko ispitivanje na 40 bolesnika s GD1.

An international, multicenter, randomized, open-label, comparative Phase 3 efficacy and safety study was conducted in newly diagnosed Ph+ CP CML patients.
Provedeno je međunarodno, multicentrično, randomizirano, otvoreno, usporedno ispitivanje, faza 3, za utvrđivanje djelotvornosti i sigurnosti u novodijagnosticiranim bolesnicima s Ph+ CP KML-om.

The safety and efficacy of Oncaspar was evaluated in an open-label, multicenter, randomized, active-controlled study Study 1.
Sigurnost i djelotvornost Oncaspara procijenjena je u otvorenom, multicentričnom, randomiziranom, aktivno kontroliranom ispitivanju Ispitivanje 1.

A multicenter, double-blind, ezetimibe-controlled, 24 week study included 248 patients with documented statin intolerance due to skeletal muscle-related symptoms.
Multicentrično, dvostruko slijepo, ezetimibom kontrolirano, 24-tjedno ispitivanje uključivalo je 248 bolesnika s dokumentiranim nepodnošenjem statina zbog simptoma povezanih sa skeletnim mišićima.

Study 02607 was a randomized, open-label, active-controlled, non-inferiority, multicenter clinical study in 159 patients previously stabilised with ERT.
Ispitivanje 02607 bilo je randomizirano, otvoreno, multicentrično kliničko ispitivanje neinferiornosti s aktivnom kontrolom na 159 bolesnika prethodno stabiliziranih s ERT-om.

The safety and efficacy of caspofungin was evaluated in paediatric patients 3 months to 17 years of age in two prospective, multicenter clinical trials.
Djelotvornost i sigurnost primjene kaspofungina procjenjivala se u pedijatrijskih bolesnika u dobi od 3 mjeseca do 17 godina u dva prospektivna, multicentrična klinička ispitivanja.

Study 2 was a randomized, controlled, multicenter study comparing the Zevalin therapeutic regimen versus treatment with rituximab.
Ispitivanje 2 bilo je randomizirano, kontrolirano, multicentrično ispitivanje radi usporedbe terapijskog protokola Zevalina i liječenja rituksimabom.

The use of single-agent crizotinib in the treatment of ROS1-positive advanced NSCLC was investigated in multicenter, multinational, single-arm Study 1001.
Primjena krizotiniba kao monoterapije u liječenju ROS1-pozitivnog uznapredovalog NSCLC-a ispitana je u multicentričnom, multinacionalnom Ispitivanju 1001 s jednom skupinom bolesnika.

Efficacy and safety were assessed in two multicenter, double-blind, placebo-controlled studies in patients with active psoriatic arthritis.
Djelotvornost i sigurnost primjene infliksimaba ispitivane su u dva multicentrična, dvostruko slijepa, placebom kontrolirana klinička ispitivanja u bolesnika s aktivnim psorijatičnim artritisom.

The radiographic response of subcutaneous administered tocilizumab was assessed in a double-blind, controlled, multicenter study in patients with active RA SC-II.
Radiološki odgovor pri primjeni supkutane formulacije tocilizumaba ocijenjen je u dvostruko slijepom, kontroliranom, multicentričnom ispitivanju u bolesnika s aktivnim RA SC-II.

A randomised, multicenter, open-label phase 3 study(PCYC-1115-CA) of IMBRUVICA versus chlorambucil was conducted in patients with treatment-naïve CLL who were 65 years of age or older.
Randomizirano, multicentrično, otvoreno ispitivanje faze 3(PCYC-1115-CA) s lijekom IMBRUVICA naspram klorambucila provedeno je u bolesnika u dobi od 65 godina ili starijih koji prehodno nisu bili liječeni za KLL.

The efficacy of Vimpat as adjunctive therapy at recommended doses(200 mg/day, 400 mg/day) was established in 3 multicenter, randomized, placebo-controlled clinical trials with a 12-week maintenance period.
Djelotvornost Vimpata kao dopunske terapije u preporučenim dozama(200 mg/dan, 400 mg/dan) dokazana je u 3 multicentrična, randomizirana, placebom kontrolirana klinička istraživanja u razdoblju od 12 tjedana.

In two multicenter, randomized, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks.
U dva multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana pivotalna ispitivanja, 234 ispitanika s nedavnim učestalim žgaravicama u anamnezi liječena su esomeprazolom u dozi od 20 mg tijekom 4 tjedna.

The safety and efficacy in the perioperative setting was evaluated in a phase 3 prospective, open-label, uncontrolled, multicenter study in male PTPs with severe and moderately severe haemophilia B using RIXUBIS.
Sigurnost i djelotvornost u perioperativnom okruženju procijenjene su u prospektivnom, otvorenom, nekontroliranom, multicentričnom ispitivanju faze 3 na muškim prethodno liječenim bolesnicima s teškom ili umjereno teškom hemofilijom B koji uzimaju RIXUBIS.

Two multicenter, placebo-controlled, double-blind 18-month studies included 732 patients with heFH receiving a maximally tolerated dose of statin, with or without other lipid-modifying therapy.
Ova dva multicentrična, placebom kontrolirana, dvostruko slijepa, 18-mjesečna ispitivanja uključivala su 732 bolesnika s heterozigotnom obiteljskom hiperkolesterolemijom koji su primali maksimalnu podnošljivu dozu statina, uz dodatnu terapiju koja modificira lipide ili bez nje.

Secondary Prophylaxis of IFI- Efficacy in HSCT recipients with prior proven or probable IFI Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI.
Vorikonazol je ispitan kao sekundarna profilaksa u otvorenom, neusporednom, multicentričnom ispitivanju u odraslih primatelja alogene HSCT s prethodnom dokazanom ili vjerojatnom invazivnom gljivičnom infekcijom.

The efficacy of ChondroCelect was studied in a phase III, multicenter, randomized, controlled trial(TIG/ACT/01/2000) and the first two years of its 4-year extension phase TIG/ACT/01/2000EXT.
Djelotvornost lijeka ChondroCelect ispitivana je u fazi III, multicentričnog, randomiziranog i kontroliranog ispitivanja(TIG/ACT/01/2000) i tijekom prve dvije godine četverogodišnje faze produžetka TIG/ACT/01/2000EXT.

TRA 2°P- TIMI 50 was a multicenter, randomized, double-blind, placebo-controlled study conducted in patients who had evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems.
Ispitivanje TRA 2°P- TIMI 50 bilo je multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno u bolesnika koji su pokazivali znakove ili su u anamnezi imali aterosklerozu koja je zahvaćala srčani, moždani ili periferni vaskularni sustav.

The effectiveness of pitolisant up to 36 mg once a day, for the treatment of narcolepsy with or without cataplexy was established in two main, 8 weeks, multicenter, randomized, double-blind, placebo-controlled, parallel group trials Harmony I and Harmony CTP.
Učinkovitost pitolizanta u dozi do 36 mg jednom dnevno za liječenje narkolepsije s katapleksijom ili bez nje, utvrđena je u dva glavna, 8-tjedna, multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja na usporednim skupinama Harmony I i Harmony CTP.

The safety and efficacy of Humira were assessed in a multicenter, randomised, double-blind study in 46 paediatric patients(6 to 17 years old) with moderate enthesitis-related arthritis.
Sigurnost i djelotvornost primjene lijeka Humira ocijenjena je u multicentričnom, randomiziranom, dvostruko slijepom ispitivanju koje je uključivalo 46 pedijatrijskih bolesnika(u dobi od 6 do 17 godina) s umjerenim artritisom povezanim s entezitisom.

In a multicenter, double-blind, placebo-controlled, 14 week study, 13 patients with heterozygous familial hypercholesterolaemia(heFH) due to gain-of-function mutations in the PCSK9 gene were randomised to receive either alirocumab 150 mg Q2W or placebo.
U multicentričnom, dvostruko slijepom, placebom kontroliranom, 14-tjednom ispitivanju provedenom u 13 bolesnika s heterozigotnom obiteljskom hiperkolesterolemijom nastalom zbog mutacija gena PCSK9 koje poboljšavaju funkciju, bolesnici su bili randomizirani za primanje alirokumaba u dozi od 150 mg jednom svaka 2 tjedna ili placeba.

The adverse reactions described in this section were identified in a single-arm, open-label, international, multicenter trial in 449 CML and Ph+ ALL patients who were resistant or intolerant to prior TKI therapy including those with a BCR-ABL T315I mutation.
Nuspojave navedene u ovom poglavlju opisane su u otvorenom, međunarodnom, multicentričnom ispitivanju na jednoj skupini u kojem je sudjelovalo 449 bolesnika s KML i Ph+ ALL rezistentnih ili intolerantnih na prethodno liječenje TKI uključujući i bolesnike s mutacijom BCR-ABL T3151.

Two randomised, open-label, multicenter Phase III trials(IFM-2005-01, MMY-3010) were conducted to demonstrate the safety and efficacy of bortezomib in dual and triple combinations with other chemotherapeutic agents, as induction therapy prior to stem cell transplantation in patients with previously untreated multiple myeloma.
Dva randomizirana, otvorena, multicentrična ispitivanja faze III(IFM-2005-01, MMY-3010) bila su provedena radi utvrđivanja sigurnosti i djelotvornosti bortezomiba u dvostrukoj ili trostrukoj kombinaciji s drugim kemoterapeuticima, kao uvodno liječenje prije transplantacije matičnih stanica u bolesnika s prethodno neliječenim multiplim mijelomom.

The safety and efficacy of Humira was assessed in an open-label, multicenter study in 32 children(2-< 4 years old or aged 4 and above weighing< 15 kg) with moderately to severely active polyarticular JIA.
Sigurnost i djelotvornost primjene lijeka Humira ocijenjena je u otvorenom, multicentričnom ispitivanju koje je uključivalo 32 djece(u dobi od 2 do manje od 4 godine ili u dobi od 4 godine i više i tjelesne težine manje od 15 kg) s umjerenim do teškim aktivnim poliartikularnim JIA.